Current clinical women's health assays focus on the detection of STI or that of HPV, but 58
vaginal specimens poses fewer barriers for women to be screened, leading to increased 148 participation rates (Verdoodt et al. 2015) . Thus, encouraging women to self-collect 149
vaginal samples for hrHPV screening may have an impact on rates of detection of 150 cervical cancer (Wong et al. 2016) . 151
The vaginal microbiome is an emerging area of research in understanding the 152 role of HPV infections and reducing the risk of cervical cancer (Mitra et al. 2016) . In this study, we tested the feasibility of a novel assay, that combines the 162 detection and identification of HPV DNA, STI-associated pathogens, and microbiome 163 analysis on samples obtained through self-sampling. We validated the performance of 164 marker gene amplification and sequencing to detect the presence and relative 165 abundance of 32 clinically important bacterial targets with high precision and accuracy. 166
In addition to detecting Lactobacillus, Sneathia, and Gardnerella spp., this test detects 167
STI-associated pathogens including Chlamydia trachomatis, Mycoplasma genitalium, 168
Neisseria gonorrhoeae, and Treponema pallidum, which cause chlamydia, genital tract 169 infections, gonorrhea, and syphilis, respectively. The performance of a novel 170 amplification and sequencing-based strategy for HPV detection and type-specific 171 identification was compared to that of the most widely used test for HPV detection in 172 cervicovaginal specimens, the Digene HC2 test. This assay is intended to complement, 173 rather than replace, current healthcare guidelines for in-clinic cervical cancer screening. Table 1 in the Supplementary Materials for more detailed   241 information about e.g. the HPV genotypes included and a list of references.
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Then, assuming amplification with up to two mismatches with the primers used, 243
we identified for each taxa the sequences that would produce an amplicon, and 244 evaluated whether that amplicon is unique to the taxon of interest (ti) or also shared by 245 sequences from different taxa (dt). The number of true positives (TP), true negatives 246 (TN), false positives (FP) and false negatives (FN) was computed for different tolerance 247 ratios for the quotient dt/ti, and subsequently in silico performance metrics were 248 assessed. Of the 73 bacterial targets initially selected, the 32 targets selected for the 249 assay had all four in silico performance metrics above 90% (Supplementary Figure 2) . In order to evaluate the performance metrics for identification of the HPV targets, 265 sequences of the L1 segment of HPV genomes from the NCBI database were used. 266
The search was filtered to sequences with length in the range 1,500-10,000 bp and with 267 correct assignment of the type of the HPV (4177 sequences). These sequences were 268 amplified in silico using the primers described below. Following these steps, we 269 generated 161,398 amplicons. These sequences were mapped using Vsearch (Rognes 270 2016) at 95% of identity against an HPV amplicon reference database consisting of the 271 amplicons produced by the reference genomes in PaVe for the 19 HPV types included 272 in our assay. The performance metrics were calculated in a manner analogous to how 273 11 they were calculated for the 16S rRNA gene targets. Briefly, the correct assignment of 274 an NCBI amplicon against the reference was counted as a true positive and an incorrect 275 assignment was considered as a false negative. Also, we considered as a false 276 negatives the genomes from NCBI that our primers could not amplify. According to this, 277 the 19 HPV types obtained values for sensitivity, specificity, positive predictive value 278 (PPV) and negative predictive values (NPV) above 90% (Supplementary Table 2 To create these mixes, each bacterial sDNA was randomly assigned to one of two 307 pools, A and B, that each contained sDNAs in equimolar amount. Each pool was serially 308 diluted in PCR grade water. Pool A dilutions were mixed 1:1 with undiluted Pool B and 309 vice versa. All pool A/B combinations were used in triplicate for DNA extraction, 310 amplification, and sequencing as described below. For each target, the LOD was 311 defined as the lowest concentration of sDNA where at least two of the three replicates 312 contained at least 2 reads for that target in a sample with 10,000 reads or more. Using 313 this LOD, we calculated a lower threshold for detection for each taxa at its LOD as the 314 LOB (48.27) plus the standard deviation of the taxa at LOD * 1.65. This threshold is 315 used to correctly assign a taxa as identified in a sample at or above its LOD. 316
For targets that had both a species and a genus level sDNA present in the mixed 317 pools A and B, a bioinformatic correction was applied. The total reads for a genus-level 318 target for which a species within that genus was also present in the mixed pools, was 319 defined as the total measured reads for the genus and subtracting all those reads 320 corresponding to species-level targets belonging to that genus in the same pool mix, 321
i.e., only reads that match to a genus and not to a species level were finally assigned to 322 the genus. The PCR products from the first amplification round were used as input for a second 364 PCR containing sample-specific forward and reverse indices and Illumina tags. PCR 365 products from this second step were pooled for sequencing. After sequencing, demultiplexing of reads according to sample-specific barcodes 374 was performed using Illumina's BCL2FASTQ algorithm. Reads were filtered using an 375 average Q-score > 30. Forward and reverse 16S rRNA gene reads were appended 376 together after removal of primers and any leading bases, and clustered using version 377 2.1.5 of the Swarm algorithm (Mahe 2014) using a distance of one nucleotide and the 378 "fastidious" and "usearch-abundance" flags. The most abundant sequence per cluster 379 was considered the real biological sequence and was assigned the count of all reads in 380 the cluster. The representative reads from all clusters were subjected to chimera 381 removal using the VSEARCH algorithm (Rognes 2016) . Reads passing all above filters 382 (filtered reads) were aligned using 100% identity over 100% of the length against the 32 383 target 16S rRNA gene sequences described above (Supplementary Table 4 ). The 384 relative abundance of each taxon was determined by dividing the count linked to that 385 taxa by the total number of filtered reads. 386 387
Sequence analysis and taxonomic annotation for HPV targets 388
Raw sequencing reads were demultiplexed using BCL2FASTQ. Primers were 389 removed using cutadapt (Martin 2011) . Trimmomatic (Bolger 2014 ) was used to remove 390 reads with a length less than 125 bp, and a mean quality score below 30. After that, 391 forward and reverse paired reads were joined using custom in-house scripts and 392 converted to a fasta file. Identical sequences were merged and written to a file in fasta 393 format and sorted by decreasing abundance using --derep_fulllength option in 394 VSEARCH (Rognes 2016) . Target sequences in the fasta files were compared to the 395 fasta-formatted query database sequences (19 HPV target sequences) using the global 396 pairwise alignment option with VSEARCH, using 95 percent sequence identity, to obtain 397 15 the counts for each HPV type within a different sample. 398
The HPV portion of the assay was considered positive if the number of sequence 399 reads assigned to the specific HPV types was above the threshold at the limit of 400 detection, and greater than a previously defined cutoff. To set this cutoff, two 401 normalization steps were employed. First, according to in silico PCR amplification, a 402 different number of combinations of primers amplify different HPV targets (e.g. HPV16 403
is amplified using 66 different combinations, while HPV43 is amplified with just 10 404 combinations), reflecting the sequence variability within the primer binding site among 405
HPVs. This also means that the spiked-in internal control and the target HPV have 406 different amplification efficiencies. To avoid this bias, the internal control (which has the 407 primer sites for HPV16) is normalized for the amplification factor (number of primer 408 combinations that generate an amplicon) of each HPV type. The number of HPV-409 assigned reads was divided by the total number of normalized reads assigned to the 410 spike, and a sample was considered HPV-positive if that ratio was above 0. Table 5 ). For example, the LOD for 481
Atopobium vaginae was identified at the 1:100 dilution, and its corresponding threshold 482 was set at 49 reads. For the other 31 taxa targeted by the assay, the threshold related 483 to LODs was in the range 49.0 to 65.2 reads (Supplementary Table 5) . for HPV in both tests) ( Table 1 ). Three sample pairs that were positive with the Digene 592 brush were HPV negative when the corresponding test was performed on extracted 593 DNA. These three samples had an average Digene RLU ratio of 1.94, suggesting that 594 these contained low levels of HPV (Figure 7) . 595 596 
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Performance of the HPV sequencing test on clinical samples 614
Using 185 vaginal specimens, the performance of the assay to detect hrHPV was 615 compared to that of the Digene HC2 hrHPV assay. The Digene test was considered 616 positive if the measured RLU was equal to or greater than the assay's cutoff (RLU ratio 617 of 1 or higher), as per the manufacturer's instructions. The assay was considered to be 618 positive for hrHPV if the normalized number of reads assigned to hrHPV types divided 619 by the number of reads assigned to a spiked-in control was greater than 0.1. Of the 185 620 samples, 145 were negative in both tests, while 36 were positive in both tests (Table 2) , 621
with an overall agreement of 97.83%, Cohen's kappa = 0.93 ± 0.064. Two samples 622
were positive in the Digene HC2 hrHPV assay but did not yield any hrHPV reads after 623 amplification and sequencing by our assay. Of these two false negatives, however, one 624 contained lrHPV 61, and the other one contained both lrHPV 30 and lrHPV 61. Although 625 these two lrHPV types were not validated for our assay, their sequences were identified 626 after amplification and genotyping. Two false positive samples were negative in the 627 Digene HC2 hrHPV assay but yielded sufficient hrHPV reads to be identified as 628 positives by our genotyping assay. One of these samples contained hrHPV type 35, and 629 the other contained hrHPV type 68. Thus, in comparison to the Digene HC2 hrHPV test, 630 the hrHPV sequencing assay had a sensitivity of 94.74% and a specificity of 98.64%. 631 632 Here, we describe a novel women's health assay combining vaginal microbiome 658 analysis, STI-associated pathogen detection, and HPV detection and identification in a 659 self-sampling format. Although each of these components have been described before, 660 to our knowledge, this assay is the first to combine all of these parts, thus offering 661 women a unique opportunity to gain a broad perspective into their vaginal and 662 reproductive health. 663
The detection of hrHPV in combination with self-sampling has been proposed as 664 an effective method for cervical cancer risk screening. Although the sensitivity of signal-665 based hrHPV detection, such as the Digene assay, in self-obtained vaginal swabs has 666 been found to be slightly lower than that in clinician-obtained cervical specimens, hrHPV 667 detection based on PCR was shown to be equally sensitive in self-sampled specimens 668 (Arbyn et al. 2014) . While this assay is not intended to replace regular cervical cancer 669 screening programs, offering women the opportunity to self-collect vaginal specimens 670 poses fewer barriers for women to be screened, and thus could lead to increased 671 participation rates. Therefore, encouraging women to self-collect vaginal samples for 672 hrHPV screening, as already implemented in numerous countries, and recommending 673 them to seek further physician examination in case of a positive result, while 674 encouraging them to participate in regular screening programs may have a positive 675 impact on rates of detection of cervical cancer, and potentially save lives (Wong et al. 676 2016) . 677
Unlike most currently available clinical assays, this assay not only detects 678
whether hrHPV is present in a sample, but also identifies the presence of specific 679 
